EyePoint Pharmaceuticals Statistics
Total Valuation
EYPT has a market cap or net worth of $977.46 million. The enterprise value is $753.52 million.
Important Dates
The next estimated earnings date is Friday, October 31, 2025, before market open.
| Earnings Date | Oct 31, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
EYPT has 80.72 million shares outstanding. The number of shares has increased by 38.62% in one year.
| Current Share Class | 80.72M |
| Shares Outstanding | 80.72M |
| Shares Change (YoY) | +38.62% |
| Shares Change (QoQ) | +0.23% |
| Owned by Insiders (%) | 0.86% |
| Owned by Institutions (%) | 57.49% |
| Float | 57.20M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 14.93 |
| Forward PS | 95.68 |
| PB Ratio | 3.35 |
| P/TBV Ratio | 4.01 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 14.52 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.00, with a Debt / Equity ratio of 0.10.
| Current Ratio | 8.00 |
| Quick Ratio | 7.73 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -13,503.64 |
Financial Efficiency
Return on equity (ROE) is -73.95% and return on invested capital (ROIC) is -45.33%.
| Return on Equity (ROE) | -73.95% |
| Return on Assets (ROA) | -37.79% |
| Return on Invested Capital (ROIC) | -45.33% |
| Return on Capital Employed (ROCE) | -70.55% |
| Revenue Per Employee | $314,533 |
| Profits Per Employee | -$1.06M |
| Employee Count | 165 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 58.46 |
Taxes
In the past 12 months, EYPT has paid $183,000 in taxes.
| Income Tax | 183,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +28.63% in the last 52 weeks. The beta is 1.97, so EYPT's price volatility has been higher than the market average.
| Beta (5Y) | 1.97 |
| 52-Week Price Change | +28.63% |
| 50-Day Moving Average | 12.77 |
| 200-Day Moving Average | 8.91 |
| Relative Strength Index (RSI) | 46.46 |
| Average Volume (20 Days) | 1,481,966 |
Short Selling Information
The latest short interest is 8.13 million, so 10.07% of the outstanding shares have been sold short.
| Short Interest | 8.13M |
| Short Previous Month | 8.00M |
| Short % of Shares Out | 10.07% |
| Short % of Float | 14.20% |
| Short Ratio (days to cover) | 6.25 |
Income Statement
In the last 12 months, EYPT had revenue of $51.90 million and -$175.38 million in losses. Loss per share was -$2.71.
| Revenue | 51.90M |
| Gross Profit | -133.71M |
| Operating Income | -189.05M |
| Pretax Income | -175.20M |
| Net Income | -175.38M |
| EBITDA | -187.14M |
| EBIT | -189.05M |
| Loss Per Share | -$2.71 |
Full Income StatementBalance Sheet
The company has $255.73 million in cash and $23.72 million in debt, giving a net cash position of $232.02 million or $2.87 per share.
| Cash & Cash Equivalents | 255.73M |
| Total Debt | 23.72M |
| Net Cash | 232.02M |
| Net Cash Per Share | $2.87 |
| Equity (Book Value) | 246.01M |
| Book Value Per Share | 3.57 |
| Working Capital | 232.08M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$190.59 million and capital expenditures -$3.45 million, giving a free cash flow of -$194.04 million.
| Operating Cash Flow | -190.59M |
| Capital Expenditures | -3.45M |
| Free Cash Flow | -194.04M |
| FCF Per Share | -$2.40 |
Full Cash Flow StatementMargins
| Gross Margin | -257.63% |
| Operating Margin | -364.27% |
| Pretax Margin | -337.58% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
EYPT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -38.62% |
| Shareholder Yield | -38.62% |
| Earnings Yield | -17.80% |
| FCF Yield | -19.69% |
Analyst Forecast
The average price target for EYPT is $27.40, which is 126.26% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $27.40 |
| Price Target Difference | 126.26% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 63.06% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 9, 2020. It was a reverse split with a ratio of 1:10.
| Last Split Date | Dec 9, 2020 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | 0 |
| Piotroski F-Score | 1 |
